Europe: CJEU rules on SPC term

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Europe: CJEU rules on SPC term

In Estonia a patent was granted on April 15 1998 followed by a marketing authorisation on June 8 2001 for a pharmaceutical composition comprising the active agent capecitabine. Based thereon a supplementary protection certificate (SPC) was requested and granted. According to Estonian national SPC regulations the SPC provided a protection term of 15 years from the date of grant of the marketing authorization, that is until June 8 2016.

On December 15 2014, however, a generic competitor wanted to bring a generic composition comprising capecitabine onto the Estonian market since, according to the competitor´s calculation, the SPC protection term ended on June 10 2013. The patentee filed an infringement suit against the competitor and the court of second instance, the Tallinn Court of Appeal, transferred the case to the CJEU for clarification of the termination date of the SPC in Estonia.

How did the discrepancy in the calculation of the termination dates arise?

On May 1 2004 Estonia became a member of the EU and according to European SPC regulations the protection term of an SPC is calculated based on the first marketing authorisation in the EU which, in the present case, was granted for capecitabine in Switzerland on June 10 1998. The CJEU hinted that Article 21(2) of SPC Regulation 469/2009 states that the regulation applies to SPCs granted according to national regulations in Estonia prior to the date of Estonia´s accession to the EU.

Further, Article 13 of this regulation in conjunction with recital 9 thereof indicates that the holder of both the patent and the SPC should not be able to enjoy more than 15 years of exclusivity from the time of the first marketing authorisation granted in the EU which, according to Article 13, has to be interpreted as the European Economic Area (EEA). Accordingly, the protection term of an SPC is calculated based on the first marketing authorisation in the EEA, even if a national SPC was granted based on a national marketing authorisation before accession of the country in question to the EU.

hermann.jpg

Bettina Hermann


V.O.Johan de Wittlaan 72517 JR The HagueThe NetherlandsTel: +31 70 416 67 11Fax: +31 70 416 67 99info@vo.euwww.vo.eu

more from across site and SHARED ros bottom lb

More from across our site

This year’s most-read stories covered uncertainty at the USPTO, a potential boycott of a major international IP conference, rankings releases, and a contempt of court proceeding
The parties have agreed on a court-guided settlement covering Pantech’s entire SEP portfolio, marking a global first
The introduction of Canada’s patent term adjustment has left practitioners sceptical about its value, with high fees and limited eligibility meaning SMEs could lose out
With the US privacy landscape more fragmented and active than ever and federal legislation stalled, lawyers at Sheppard Mullin explain how states are taking bold steps to define their own regimes
Viji Krishnan of Corsearch unpicks the results of a survey that reveals almost 80% of trademark practitioners believe in a hybrid AI model for trademark clearance and searches
News of Via Licensing Alliance selling its HEVC/VCC pools and a $1.5 million win for Davis Polk were also among the top talking points
The winner of a high-profile bidding war for Warner Bros Discovery may gain a strategic advantage far greater than mere subscriber growth - IP licensing leverage
A vote to be held in 2026 could create Hogan Lovells Cadwalader, a $3.6bn giant with 3,100 lawyers across the Americas, EMEA and Asia Pacific
Varuni Paranavitane of Finnegan and IP counsel Lisa Ribes compare and contrast two recent AI copyright decisions from Germany and the UK
Exclusive in-house data uncovered by Managing IP reveals French firms underperform on providing value equivalent to billing costs and technology use
Gift this article